scholarly article | Q13442814 |
P50 | author | Kang-Yi Su | Q56989064 |
Wei-Yu Liao | Q57020031 | ||
Chong-Jen Yu | Q42255080 | ||
P2093 | author name string | Hsuan-Yu Chen | |
Gee-Chen Chang | |||
Sung-Liang Yu | |||
Tsung-Ying Yang | |||
Jeng-Sen Tseng | |||
Kun-Chieh Chen | |||
Kuo-Hsuan Hsu | |||
Chi-Ren Tsai | |||
Jeremy Jw Chen | |||
Meen-Hsin Tsai | |||
P2860 | cites work | Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. | Q53561291 |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. | Q33402098 | ||
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. | Q34328665 | ||
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer | Q35196345 | ||
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line | Q36040619 | ||
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed | Q36766720 | ||
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed | Q36821156 | ||
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer | Q37609860 | ||
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. | Q37659062 | ||
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? | Q37760357 | ||
Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing | Q37994383 | ||
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference? | Q38080824 | ||
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer | Q43292962 | ||
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. | Q44845388 | ||
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial | Q44886865 | ||
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations | Q45155265 | ||
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. | Q45964243 | ||
Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs | Q46144064 | ||
Retrospective study of erlotinib in patients with advanced squamous lung cancer | Q48713500 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adenocarcinoma | Q356033 |
P304 | page(s) | 799-805 | |
P577 | publication date | 2014-05-23 | |
P1433 | published in | OncoTargets and Therapy | Q7092081 |
P1476 | title | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma | |
P478 | volume | 7 |
Q38676692 | Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). |
Q36413062 | Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors |
Q52562714 | Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. |
Q41728235 | Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations |
Q38486882 | Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. |
Q26741318 | Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications |
Q28075291 | Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options |
Search more.